Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.

BMC cancer - 21 May 2015

Meng Fanying, Bhupathi Deepthi, Sun Jessica D, Liu Qian, Ahluwalia Dharmendra, Wang Yan, Matteucci Mark D, Hart Charles P

Abstract excerpt

BACKGROUND: The hypoxia-activated prodrug TH-302 is reduced at its nitroimidazole group and selectively under hypoxic conditions releases the DNA cross-linker bromo-isophosphoramide mustard (Br-IPM). Here, we have explored the effect of Chk1 inhibition on TH-302-mediated pharmacological activities. METHODS: We employed in vitro cell viability, DNA damage, cellular signaling assays and the in vivo HT29 human tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CDC2 Protein Kinase
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Checkpoint Kinase 1

Share to HT29 Cells

Share to Nitroimidazoles

Share to Rad51 Recombinase

Share to Thiophenes

Source

Open in PubMed Open full text

Identifiers

PMID: 25994202
DOI: 10.1186/s12885-015-1387-6
PMCID: PMC4453293

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.PMID 25994202Read ↗

Chk1 Inhibitors for Novel Cancer TreatmentSemantic proximity Read ↗

CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.Semantic proximity Read ↗

Novel Checkpoint 1 InhibitorsSemantic proximity Read ↗

Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancerSemantic proximity Read ↗

p53‐dependent G1 arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitorsSemantic proximity Read ↗

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons <i>In vitro</i> and <i>In vivo</i>Semantic proximity Read ↗

Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.Semantic proximity Read ↗

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1Semantic proximity Read ↗

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.Semantic proximity Read ↗

The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human NeuroblastomaSemantic proximity Read ↗

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapySemantic proximity Read ↗

Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.